Testing the neural sensitization and kindling hypothesis for illness from low levels of environmental chemicals

Environmental Health Perspectives

Volumn 105, Issue SUPPL. 2, 1997, Pages 539-547

  Bell, Iris R ^a,i   Rossi III, John ^b   Gilbert, Mary E ^c   Kobal, Gerd ^d   Morrow, Lisa A ^e   Newlin, David B ^f   Sorg, Barbara A ^g   Wood, Ronald W ^h  

^a UNIVERSITY OF ARIZONA   (United States)

^b NAVAL MEDICAL RESEARCH CENTER   (United States)

^c U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^g WASHINGTON STATE UNIVERSITY   (United States)

^h NEW YORK UNIVERSITY   (United States)

ⁱ SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

Author keywords

Animal; Human; Kindling; Low level exposures; Mesolimbic; Psychophysiology; Sensitization; Time factors

Indexed keywords

ENVIRONMENTAL CHEMICAL;

CONFERENCE PAPER; ETIOLOGY; HYPOTHESIS; KINDLING; LIMBIC SYSTEM; MULTIPLE CHEMICAL SENSITIVITY; NEUROSCIENCE; PRIORITY JOURNAL; PSYCHOPHYSIOLOGY; SENSITIZATION; SUBSTANCE ABUSE; TEMPORAL LOBE EPILEPSY; TIME;

ANIMALIA;

EID: 0030908038     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.97105s2539     Document Type: Conference Paper

References (103)

1. Groves PM, Thompson RF. Habituation: a dual-process theory. Psychol Rev 77:419-450 (1970).
2. Antelman SM. Time-dependent sensitization as the cornerstone for a new approach to pharmacotherapy: drugs as foreign/stressful stimuli. Drug Devel Res 14:1-30 (1988).
3. Antelman SM. Time-dependent sensitization in animals: a possible model of multiple chemical sensitivity in humans. Toxicol Ind Health 10:335-342 (1994).
4. Post RM. Intermittent versus continuous stimulation: effect of the interval on the development of sensitization or tolerance. Life Sci 26:1275-1282 (1980).
5. Sorg BA, Willis JR, Nowatka TC, Ulibarri C, See RE, Westberg HH. A proposed animal neurosensitization model for multiple chemical sensitivity in studies with formalin. Toxicology 111:135-145 (1995).
6. Kalivas PW, Sorg BA, Hooks MS. The pharmacology and neural circuitry of sensitization to psychostimulants. Behav Pharmacol 4:315-334 (1993).
7. Bell IR. Neuropsychiatric aspects of sensitivity to low level chemicals: a neural sensitization model. Toxicol Ind Health 10:277-312 (1994).
8. Stewart J, Badiani A. Tolerance and sensitization to the behavioral effects of drugs. Behav Pharmacol 4:289-312 (1993).
9. Stewart J, Vezina P. Extinction procedures abolish conditioned stimulus control but spare sensitized responding to amphetamine. Behav Pharmacol 2:65-71 (1991).
10. Jodogne C, Marinelli M, LeMoal M, Piazza PV. Animals pre-disposed to develop amphetamine self-administration show higher susceptibility to develop contextual conditioning of both amphetamine-induced hyperlocomotion and sensitization. Brain Res 657:236-244 (1994).
11. Antelman SM, Cunnick JE, Lysle DT, Caggiula AR, Knopf S, Kocan DJ, Rabin BS, Edwards DJ. Immobilization 12 days (but not one hour) earlier enhanced 2-deoxy-D-glucose-induced immunosuppression: evidence for stressor-induced time-dependent sensitization of the immune system. Prog Neuropsychopharmacol Biol Psychiatry 14:579-590 (1990).
12. Post RM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 149:999-1010 (1992).
13. Altesdatter JE, Kalivas PW. Involvement of N-methyl-D-aspartate receptor stimulation in the ventral tegmental area and amygdala in behavioral sensitization to cocaine. J Pharmacol Exp Ther 267:486-495 (1993).
14. Itzhak Y. Blockade of sensitization to the toxic effects of cocaine in mice by nitric oxide synthase inhibitors. Pharmacol Toxicol 74:162-166 (1994).
15. Karler R, Finnegan KT, Calder LD. Blockade of behavioral sensitization to cocaine and amphetamine by inhibitors of protein synthesis. Brain Res 603:19-24 (1993).
16. Heidbreder C, Goldberg SR, Shippenberg TS. Inhibition of cocaine-induced sensitization by the delta-opioid receptor antagonist naltrindole. Eur J Pharmacol 243:123-127 (1993).
17. Goddard GV. Development of epileptic seizures through brain stimulation at low intensity. Nature 214:1020-1021 (1967).
18. Rossi J. Sensitization induced by kindling and kindling-related phenomena as a model for multiple chemical sensitivity. Toxicology 111:87-100 (1996).
19. Gilbert ME. Neurotoxicants and limbic kindling. In: The Vulnerable Brain and Environmental Risks. Vol 1: Malnutrition and Hazard Assessment (Isaacson RL, Jensen KF, eds). New York:Plenum Press, 1992;173-193.
20. Gilbert, ME. Repeated exposure to lindane leads to behavioral sensitization and facilitates electrical kindling. Neurotoxicol Teratatol 17:131-141 (1995).
21. Kay LM. Support for the kindling hypothesis in multiple chemical sensitivity syndrome (MCSS) induction. Society for Neuroscience 22:1825 (1996).
22. Bell IR, Miller CS, Schwartz GE. An olfactory-limbic model of multiple chemical sensitivity syndrome: possible relationships to kindling and affective spectrum disorders. Biol Psychiatry 32:218-242 (1992).
23. Adamec RE. Does kindling model anything clinically relevant? Biol Psychiatry 27:249-279 (1990).
24. Ashford NA, Miller CS. Chemical Exposures. Low Levels and High Stakes. New York:Van Nostrand Reinhold, 1991.
25. Black DW, Rathe A, Goldstein RB. Environmental illness. A controlled study of 26 subjects with 20th century disease. JAMA 264:3166-3170 (1990).
26. Simon GE, Katon WJ, Sparks PJ. Allergic to life: psychological factors in environmental illness. Am J Psychiatry 147:901-906 (1990).
27. Simon GE, Daniell W, Stockbridge H, Claypoole K, Rosenstock L. Immunologic, psychological, and neuropsychological factors in multiple chemical sensitivity. A controlled study. Ann Int Med 19:97-103 (1993).
28. Dager SR, Holland JP, Cowley DS, Dunner DL. Panic disorder precipitated by exposure to organic solvents in the work place. Am J Psychiatry 144:1056-1058 (1987).
29. Sparks PJ, Daniell W, Black DW, Kipen HM, Altman LC, Simon GE, Terr AI. Multiple chemical sensitivity syndrome: a clinical perspective. I: Case definition, theories of pathogenesis, and research needs. J Occup Med 36:18-730 (1994).
30. Leyton, M. Belanger C, Martial J, Beaulieu S, Corin E, Pecknold J, Kin NMK, Meaney M, Thavundayil J, Larue S, Nair NPV. Cardiovascular, neuroendocrine, and monoaminergic responses to psychological stressors: possible differences between remitted panic disorder patients and healthy controls. Biol Psychiatry 40:353-360 (1996).
31. Staudenmayer H, Selner ME, Selner JC. Adult sequelae of childhood abuse presenting as environmental illness. Ann Allergy 71:538-546 (1993).
32. Lemieux AM, Coe CL. Abuse-related posttraumatic stress disorders: evidence for chronic neuroendocrine activation in women. Psychosom Med 57:105-115 (1995).
33. Teicher MH, Glod CA, Surey J, Swett C. Early childhood abuse and limbic system ratings in adult psychiatric outpatients. J Neuropsychiatry Clin Neurosci 5:301-306 (1993).
34. Yehuda R, Antelman SM. Criteria for rationally evaluating animal models of posttraumatic stress disorder. Biol Psychiatry 33:479-486 (1993).
35. Bell IR. Clinically relevant EEG studies and psychophysiological findings: possible neural mechanisms for multiple chemical sensitivity. Toxicology 111:101-117 (1996).
36. Bell IR, Schwartz GE, Baldwin CM, Hardin EE, Klimas NG, Kline JP, Patarca R, Song ZY. Individual differences in neural sensitization and the role of context in illness from low level environmental chemical exposures. Environ Health Perspect 105(Suppl 2):457-466 (1997).
37. Bell IR, Schwartz GE, Baldwin CM, Hardin EE. Neural sensitization and physiological markers in multiple chemical sensitivity. Regulat Toxicol Pharmacol 24:S39-S47 (1996).
38. Camp DM, Robinson TE. Susceptibility to sensitization. I: Sex differences in the enduring effects of chronic D-amphetamine treatment on locomotion, stereotyped behavior and brain monoamines. Behav Brain Res 30:55-68 (1988).
39. Antelman SM, Caggiula AR, Kocan D, Knopf S, Meyer D, Edwards DJ, Barry H. One experience with lower or higher intensity stressors, respectively enhances or diminishes responsiveness to haloperidol weeks later: implications for understanding drug variability. Brain Res 566:276-283 (1991).
40. Antelman SM, Caggiula AR, Kiss S, Edwards DJ, Kocan D, Stiller R. Neurochemical and physiological effects of cocaine oscillate with sequential drug treatment: possibly a major factor in drug variability. Neuropharmacol 12:297-306 (1995).
41. Hooks MS, Jones GH, Neuill DB, Justice JB. Individual differences in amphetamine sensitization: dose-dependent effects. Pharmacol Biochem Behav 41:203-210 (1992).
42. Newlin DB, Thomson JB. Chronic tolerance and sensitization to alcohol in sons of alcoholics. Alcohol Clin Exp Res 15:399-405 (1991).
43. Badiani A, Browman KE, Robinson TE. Influence of novel versus home environments on sensitization to the psychomotor stimulant effects of cocaine and amphetamine. Brain Res 674:291-298 (1995).
44. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th ed. Washington:American Psychiatric Press, 1994.
45. First MB, Gibbon M, Spitzer RL, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders: Clinician Version. Washington:American Psychiatric Press, 1996.
46. Miller CS, Mitzel HC. Chemical sensitivity attributed to pesticide exposure versus remodeling. Arch Environ Health 50:119-129 (1995).
47. Buchwald D, Garrity D. Comparison of patients with chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivities. Arch Intern Med 154: 2049-2053 (1994).
48. Nethercott JR, Davidoff LL, Curbow B, Abbey H. Multiple chemical sensitivities syndrome: toward a working case definition. Arch Environ Health 48:19-26 (1993).
49. Fiedler N, Maccia C, Kipen H. Evaluation of chemically sensitive patients. J Occup Med 34:529-536 (1992).
50. Fiedler N, Kipen H, DeLuca J, Kelly-McNeil K, Natelson B. Neuropsychology and psychology of MCS. Toxicol Ind Health 10:545-554 (1994).
51. Fiedler N, Kipen HM, DeLuca J, Kelly-McNeil K, Natelson B, A controlled comparison of multiple chemical sensitivities and chronic fatigue syndrome. Psychosom Med 58:38-49 (1996).
52. Bell IR, Peterson JM, Schwartz GE. Medical histories and psychological profiles of middle-aged women with and without self-reported illness from environmental chemicals. J Clin Psychiatry 56:151-160 (1995).
53. Smith GR, Brown FW. Screening indexes in DSM-III-R somatization disorder. Gen Hosp Psychiatry 12:148-152 (1990).
54. Dahlstrom WG, Welsh GS, Dahlstrom LE. An MMPI Handbook. Minneapolis:University of Minnesota Press, 1972.
55. Symptom Checklist 90 (revised). Towson, MD:Clinical Psychometric Research, 1983.
56. Bell IR, Schwartz GE, Baldwin CM, Hardin EE, Kline JP. Unpublished data.
57. Beck AT, Ward CH, Mendelson M, Mock JE, Erbaugh J. An inventory measuring depression. Arch Gen Psychiatry 4:561-571 (1961).
58. Spielberger CD. State-Trait Anxiety Inventory. Odessa, FL: Psychological Assessment Resources, 1996.
59. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278-296 (1967).
60. Bell IR, Walsh ME, Goss A, Gersmeyer J, Schwartz GE, Kanof P. Unpublished data.
61. Bell IR, Schwartz GE, Peterson JM, Amend D. Self-reported illness from chemical odors in young adults without clinical syndromes or occupational exposures. Arch Environ Health 48:6-13 (1993).
62. Bell IR, Schwartz GE, Peterson JM, Amend D, Stini WA. Possible time-dependent sensitization to xenobiotics: self-reported illness from chemical odors, foods, and opiate drugs in an older adult population. Arch Environ Health 48:315-327 (1993).
63. Bell IR, Schwartz GE, Amend D, Peterson JM, Stini WA. Sensitization to early life stress and response to chemical odors in older adults. Biol Psychiatry 35:857-863 (1994).
64. Bell IR, Miller CS, Schwartz GE, Peterson JM, Amend D. Neuropsychiatric and somatic characteristics of young adults with and without self-reported chemical odor intolerance and chemical sensitivity. Arch Environ Health 51:9-21 (1996).
65. Bell IR, Hardin EE, Baldwin CM, Schwartz GE. Increased limbic system symptomatology and sensitizability of young adults with chemical and noise sensitivities. Environ Res 70:84-97 (1995).
66. Meggs WJ, Dunn KA, Bloch RM, Goodman PE, Davidoff AL. Prevalence and nature of allergy and chemical sensitivity in a general population. Arch Environ Health 51:275-282 (1996).
67. Wallace L, Nelson CJ, Kollander M, Leaderer B, Bascom R, Dunteman G. Indoor Air Quality and Work Environment Study. Multivariate Statistical Analysis of Health, Comfort, and Odor Perceptions As Related to Personal and Workplace Characteristics. Vol 4. Research Triangle Park, NC:U.S. Environmental Protection Agency, 1991.
68. Morrow LA, Steinhauer SR. Alterations in heart rate and pupillary response in persons with organic solvent exposure. Biol Psychiatry 37:721-730 (1995).
69. Bell IR, Schwartz GE, Bootzin RR, Wyatt JK. Time-dependent sensitization of heart rate and blood pressure over multiple laboratory sessions in elderly individuals with chemical odor intolerance. Arch Environ Health (in press).
70. von Euler G, Ogren S, Eneroth P, Fuxe K, Gustafsson J. Persistent effects of 80 ppm toluene on dopamine-regulated locomotor activity and prolactin secretion in the male rat. Neurotoxicology 15:621-624 (1994).
71. Poulton EC, Freeman PR. Unwanted asymmetrical transfer effects with balanced experimental designs. Psychol Bull 66:1-8 (1966).
72. Poulton EC. Range effects in experiments on people. Am J Psychol 88:3-32 (1975).
73. Poulton EC. Unwanted range effects from using within-subject experimental designs. Psychol Bull 80:113-121 (1973).
74. Antelman SM, Kocan D, Knopf, S, Edwards DJ, Caggiula AR. One brief exposure to a psychological stressor induces long-lasting, time-dependent sensitization of both the cataleptic and neurochemical responses to haloperidol. Life Sci 51:261-266 (1992).
75. Miller C, Ashford N, Doty R, Lamielle M, Otto D, Rahill A, Wallace L. Working Group Report 1 : Empirical approaches for the investigation of toxicant-induced loss of tolerance. Environ Health Perspect 105(Suppl 2):515-519 (1997).
76. Miller CS. Chemical sensitivity: history and phenomenology. Toxicol Ind Health 10:253-276 (1994).
77. Katon W, Raskind M. Treatment of depression in the medically ill elderly with methylphenidate. Am J Psychiatry 137:963-965 (1980).
78. Denicoff KD, Durkin TM, Lotze MT, Quinlan PE, Davis CL, Listwak SJ, Rosenberg SA, Rubinow DR. The neuroendocrine effects of interleukin-2 treatment. J Clin Endocrinol Metab 69:402-410 (1989).
79. Bell IR, Bootzin RR, Davis T, Hau V, Ritenbaugh C, Johnson KA, Schwartz GE. Time-dependent sensitization of plasma beta-endorphin in community elderly with self-reported environmental chemical odor intolerance. Biol Psychiatry 40:134-143 (1996).
80. Molhave L, Jensen JG, Larsen S. Subjective reactions to volatile organic compounds as air pollutants. Atm Environ 25a:1283-1293 (1991).
81. van de Kar LD, Peichowski RA, Rittenhouse, PA, Gray TS. Amygdaloid lesions: differential effect on conditioned stress and immobilization-induced increases in corticosterone and renin secretion. Neuroendocrinology 54:89-95 (1991).
82. Brown EE, Robertson GS, Fibiger HC. Evidence for conditioned neuronal activation following exposure to a cocaine-paired environment: role of forebrain limbic structures. J Neurosci 12:4112-4121 (1992).
83. Kobal G, Hummel T. Olfactory (chemosensory) event-related potentials. Toxicol Ind Health 10:587-596 (1994).
84. Morrow LA, Steinhauer SR, Hodgson MJ. Delay in P300 latency in patients with organic solvent exposure. Arch Neurol 49:315-320 (1992).
85. Morrow LA, Steinhauer SR, Condray R. Differential associations of P300 amplitude and latency with cognitive and psychiatric function in solvent-exposed adults. J Neuropsychiatry Clin Neurosci 8:446-449 (1996).
86. Lorig TS, Huffman E, DeMartino A, DeMarco J. The effects of low concentration odors on EEG activity and behavior. J Psychophysiol 5:67-77 (1991).
87. Bell IR, Bootzin RR, Ritenbaugh C, Wyatt JK, DeGiovanni G, Kulinovich T, Anthony JL, Kuo TF, Rider SP, Peterson JM, Schwartz GE, Johnson KA. A polysomnographic study of sleep disturbance in community elderly with self-reported environmental chemical odor intolerance. Biol Psychiatry 40:123-133 (1996).
88. Ryan CM, Morrow LA, Hodgson M. Cacosmia and neurobehavioral dysfunction associated with occupational exposure to mixtures of organic solvents. Am J Psychiatry 145:1442-1445 (1988).
89. Morrow, LA, Robin, N, Hodgson, MJ, Kamis, H. Assessment of attention and memory efficiency in persons with solvent neurotoxicity. Neuropsychologia 30:911-922 (1992).
90. Morrow LA, Ryan CM, Hodgson MJ, Robin N. Alterations in cognitive and psychological functioning after organic solvent exposure. J Occup Med 32:444-450 (1990).
91. Morrow LA, Kamis H, Hodgson MJ. Psychiatric symptomatology in persons with organic solvent exposure. J Consult Clin Psychol 61:171-174 (1993).
92. Tolliver BK, Belknap JK, Woods WE, Carney JM. Genetic analysis of sensitization and tolerance to cocaine. J Pharmacol Exp Ther 270:1230-1238 (1994).
93. 3H] dopamine release. Brain Res 566:255-264 (1991).
94. Robinson TE, Becker JB, Presty SK. Long-term facilitation of amphetamine-induced rotational behavior and striatal dopamine release produced by a single exposure to amphetamine: sex differences. Brain Res 253:231-241 (1982).
95. Bell IR, Wyatt JK, Bootzin RR, Schwartz GE. Slowed reaction time performance on a divided attention task in elderly with environmental chemical odor intolerance. Int J Neurosci 84:127-134 (1995).
96. Wang HW, Wysocki CJ, Gold GH. Induction of olfactory receptor sensitivity in mice. Science 260:998-1000 (1993).
97. Stevens DA, O'Connell RJ. Enhanced sensitivity to androstenone following regular exposure to pemenone. Chemical Senses 20:413-419 (1995).
98. Evans J, Hastings L. Accumulation of CD(II) in the CNS depending on the route of administration: intraperitoneal, intratracheal, or intranasal. Fundam Appl Toxicol 19:275-278 (1992).
99. Ghantous H, Dencker L, Gabrielsson J, Danielsson BRG, Bergman K. Accumulation and turnover of metabolites of toluene and xylene in nasal mucosa and olfactory bulb in the mouse. Pharmacol Toxicol 66:87-92 (1990).
100. Brittebo EB. Metabolism of xenobiotics in the nasal olfactory mucosa: implications for local toxicity. Pharmacol Toxicol 72 (Supp 13):50-52 (1993).
101. Berliner DL, Monti-Bloch L, Jennings-White C, Diaz-Sanchez V. The functionality of the human vomeronasal organ (VNO): evidence for steroid receptors. J Steroid Biochem Molec Biol 58:259-265 (1996).
102. Wood RW. Determinants of irritant termination behavior. Toxicol Appl Pharmacol 61:260-268 (1981).
103. Wood RW, Coleman JB. Behavioral evaluation of irritant properties of formaldehyde. Toxicol Appl Pharmacol 130:67-72 (1995).